Karuna Therapeutics, Inc. Stock News

Karuna Therapeutics, Inc. (NASDAQ:KRTX ) Q1 2023 Earnings Conference Call May 4, 2023 8:00 AM ET Company Participants Alexis Smith - Senior Director of Investor Relations Bill Meury - President and Ch

Karuna Therapeutics (KRTX) reports encouraging first-quarter 2023 results. The company beats estimates for earnings and sales.

BOSTON--(BUSINESS WIRE)--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric a

89bio's stock is up more than 21% this year. Karuna Therapeutics says it plans to file an NDA for its lead therapy this year.

BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psy

BOSTON--(BUSINESS WIRE)--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric a

Karuna Therapeutics focuses on therapies to treat neurological conditions. The stock is up more than 52% over the past year.

Data from a late-stage study shows that treatment with Karuna's (KRTX) lead candidate, KarXT, led to an early and sustained statistically significant reduction of symptoms of schizophrenia.

The stock price of Karuna Therapeutics Inc (NASDAQ: KRTX) fell by 3.56% after hours in the most recent trading session. This is why.

Karuna Therapeutics (NASDAQ: KRTX ) stock is on the move Monday after releasing results from a Phase 3 clinical trial for KarXT. KarXT is a drug in development by the company to treat adults with schi

Karuna Therapeutics said its third study of a schizophrenia treatment succeeded, and KRTX stock surged to a three-month high Monday. The post Karuna Surges To Three-Month High On Another Win In Schizo

Shares of Karuna Therapeutics Inc. KRTX, +1.21% rallied about 14% in premarket trading on Monday after the company said its experimental treatment for adults with schizophrenia met the primary endpoin

Karuna Therapeutics (KRTX) reports encouraging fourth-quarter 2022 results. The company beats estimates for earnings and sales.

As Covid-19 problems settle into recurring problems, other biotechnology targets become more active treatment subjects. The psychiatric and neurological conditions of Karuna's focus are receiving incr

There are no sure things in the stock market. But here's an almost sure thing: Investing in stocks that sell for 100 times revenue will lead you to grief.